Introduction
Patients with heart failure (HF) have a high rate of hospitalization. Cardiovascular hospitalizations (CVHs) of patients with HF account for more than 80% of the total amount spent on the care of these patients. 1, 2 The hospitalization rate and death rate of patients with HF are especially high after discharge for CVH. This high event rate is observed after hospitalization not only due to worsening HF but also due to other causes. The concept of 'hospitalized HF' has been promoted to better characterize this fact. 3, 4 Strong data exist to support the use of angiotensin-converting enzyme inhibitor (ACE-I), angiotensin receptor blocker (ARB), betablockers (BBs), and mineralocorticoid receptor antagonists (MRAs) in patients with chronic HF. 5 MRAs added to standard therapy reduce mortality as well as hospitalization for chronic HF in patients with a reduced left ventricular ejection fraction (LVEF), irrespective of the severity of symptoms. 6, 7 Disappointingly, MRAs are prescribed at discharge in less than one-third of the eligible patients, representing even worse underutilization than for ACE-I/ ARB and BBs. 8 This may be because there are few data specifically about the effectiveness of any of these treatments, including MRAs, in relation to timing of initiation either during or after hospitalization. 9, 10 We therefore examined the effect of eplerenone according to the timing of its use after hospital discharge in EMPHASIS-HF. The EMPHASIS-HF trial 6 compared eplerenone with placebo added to standard therapy in patients with New York Heart Association (NYHA) class II HF and LVEF ≤ 35%.
Methods
The design and results of EMPHASIS-HF 6 have been published. Importantly, in most patients, and per-protocol, therapy was initiated within 180 days after a CVH.
Patient selection
Patients included in EMPHASIS-HF were at least 55 years of age; in NYHA functional class II; had an LVEF ≤30% (or if between 31 and 35%, the QRS duration had to be .130 ms); and were treated with the recommended or maximally tolerated dose of an ACE-I/ARB and a BB (unless contraindicated). In addition, included patients had been hospitalized for a cardiovascular reason within the past 6 months or had a B-type natriuretic peptide (BNP) level ≥250 pg/mL or N-terminal pro-BNP level ≥500 pg/mL for males and ≥750 pg/mL for females.
Patients with an estimated glomerular filtration rate (eGFR) ,30 mL/ min/1.73 m 2 need a potassium sparing diuretic, or any other significant comorbid condition was excluded.
In this post hoc analysis of the EMPHASIS-HF trial, the 399 patients who were recruited on the basis of an elevated BNP rather than a qualifying CVH have been excluded. We studied the remaining 2338 patients who had been hospitalized for a CV reason within 6 months from randomization.
Each centre's Ethics Committee approved the trial, and all patients provided written informed consent.
Timing of initiation of eplerenone
As only the time of admission, and not time of discharge date of the qualifying CVH, was recorded in the case record form, we considered timing since the qualifying CVH date of admission as a proxy variable. The population was divided into two groups according to the median time from the qualifying CVH (42 days).
Endpoint assessment
The primary efficacy endpoint for the EMPHASIS-HF trial was the composite of cardiovascular mortality or hospitalization for HF. Hospitalization for HF and all-cause mortality were secondary endpoints. All endpoints were independently adjudicated by an independent Critical Event Committee and were used for this post hoc analysis.
Statistical analysis
Baseline characteristics were expressed as mean (standard deviation) or proportions as appropriate.
Univariable time-to-event comparisons were made using log-rank test and univariable Cox proportional hazards models. Proportional hazards assumptions were verified. Interactions between the timing of the initiation of eplerenone since CV event and the effect of eplerenone on clinical outcomes were assessed by introducing an interaction term (time since qualifying CV event ≥42 days × eplerenone) within the models. Regardless of the P-value associated with this interaction term, we reported the associations between eplerenone and survival in each of the groups of time since CV events (i.e. ,42 or 42+ days). Survival probabilities were estimated using the Kaplan -Meier method.
As reported previously, 11 analyses of all HF hospitalizations, including repeats, were carried out using negative binomial regression models.
We compared the incidence rates of HF hospitalizations in patients initiated on eplerenone and placebo, respectively, within 42 and after 42 days since qualifying CV event. The negative binomial method allows for the different individual patient tendencies (frailties) for repeat hospitalizations, i.e. it takes into account the skewness in the distribution of number of HF hospitalizations. All analysis was run in SAS version 9.2 and Stata/MP version 12.
Results
Comparison of baseline characteristics of patients in the <42 and 421 days groups
Half of the patients in the ,42 days group had a time since qualifying CVH less than 12 days ( In addition, we did not identify clinically significant differences according to treatment allocation in the ,42 and 42+ days groups.
Comparison of event rate of patients in the <42 and 421 days groups
Overall, during follow-up, 354 patients (15.1%) had CV death, 56 patients (2.4%) had non-CV death, and 415 patients (17.6%) had a first HF hospitalization. When repeat HF hospitalizations were considered, 722 HF hospitalizations were identified.
Regardless of the event considered, the event rates were lower in the 42+ days group (Figure 1 ). The primary outcome (i.e. composite of CV death and hospitalization for HF) was met in 277 patients (23.6%) in the 42+ days group and in 332 patients (28.6%) in the ,42 days group, resulting, respectively, in rates of 14.1 and 11. 
Effect of eplerenone on outcomes in the <42 and 421 days groups
Regardless of the event considered, cumulative incidences of events in patients treated with eplerenone were lower than the rates observed in patients allocated to placebo in both the ,42 and the 42+ days groups ( Figure 2 ).
In the ,42 days group, 139 patients (24.4%) in the eplerenone arm and 193 patients (32.5%) in the placebo arm met the primary outcome, resulting, respectively, in rates of 17.0 and 11.4 events per 100 person-years of follow-up (HR ¼ 0.68, 95% CI ¼ 0.55 -0.85, Figure 3 ). In the 42+ days group, 121 patients (20.5%) in the eplerenone arm and 156 patients (26.6%) in the placebo arm met the primary outcome, resulting, respectively, in rates of 13 0.94). There was no significant interaction between the groups of time since the qualifying CVH and eplerenone treatment with regard to the primary outcome (P ¼ 0.65).
The relative effect of eplerenone on all other outcomes was similar in the ,42 and 42+ days groups: HF hospitalization (HR ¼ 0.64 in the ,42 days group vs. 0.68 in the 42+ days group, P for interaction ¼ 0.44, Figure 3) , repeat HF hospitalization (RR ¼ 0.63 in the ,42 days group vs. HR ¼ 0.49 in the 42+ days group, P for interaction ¼ 0.13), and all-cause mortality (HR ¼ 0.80 in the ,42 days group vs. 0.85 in the 42+ days group, P for interaction ¼ 0.40).
The absolute rate reduction with eplerenone was 25. Sensitivity analysis: effect of eplerenone on outcomes in the <30 and 301 days groups
As a sensitivity analysis, we used a 30-day cut-off rather than the 42-day cut-off. In this analysis, the relative effect of eplerenone on all outcomes was not significantly different in the ,30 and 30+ days groups (all P . 0.05). Yet, the relative effect of eplerenone on the primary outcome tended to be greater in the ,30 days group (HR ¼ 0.60, 95% CI ¼ 0.47 -0.76) than in the 30+ days group (HR ¼ 0.81, 95% CI ¼ 0.65 -1.00, P for interaction ¼ 0.07).
Safety of eplerenone in the <42 and 421 days groups
The incidence of adverse events was low in both groups and was similar in the ,42 and 42+ days groups ( Table 2) . Higher rates of hyperkalaemia were reported in the eplerenone group. However, the association between eplerenone and the rate of adverse events was unaffected by the timing since qualifying hospitalization (all P-values for interaction .0.20, Table 2 ).
Discussion
The main result of this post hoc analysis of the EMPHASIS-HF study is that eplerenone improves survival and prevents re-admission when initiated soon after a CVH in patients with systolic HF and mild symptoms. The magnitude of the benefit from eplerenone was similar, on a relative scale, whether initiated ,42 or 42+ days after the qualifying CVH.
Strong data exist to support the use of ACE-I, ARBs, BBs, and MRAs in patients with chronic systolic HF. Clinical trials that demonstrated the clinical benefits of these medications in chronic HF were conducted in HF outpatients. The design of these trials made Figure 1 Event rates and corresponding HRs according to time since the qualifying CVH for the primary endpoint (CV mortality/HF hospitalization) and the secondary endpoints of hospitalization for heart failure and all-cause mortality. Unadjusted HR and 95% CI from the Cox proportional hazards regression model are provided for first events. Rate ratio and 95% CI from the negative binomial model are provided for repeat hospitalizations. Rates were calculated as the total number of hospitalizations divided by the total follow-up time in each group. CIs of rates are also provided.
Clinical benefits of eplerenone in patients with systolic HF physicians reluctant to introduce ACE-I 12 or BBs, 13 early after HF worsening. Regarding BBs, a trial was specifically designed to compare the effect of an in-hospital initiation of carvedilol with a later initiation of carvedilol performed in an outpatient setting. 14 This trial was not powered to assess an impact of the timing of BBs initiation on outcome. However, it demonstrated that a much higher proportion of patients were treated at 60 days after discharge if BBs were initiated during the hospital stay. These results favouring an early introduction of HF treatments are also supported by observational data powered to report clinical outcomes. After a careful propensity score-based analysis that decreases treatment attribution bias, BBs initiated before or at discharge are associated with lower mortality and re-hospitalization following acute HF hospitalization. 9, 15 Similar observational results support the use of ACE-I at discharge from HF hospitalization. 16 Consequently, the 2012 ESC guidelines 5 no longer address safety issues of in-hospital initiation of HF treatment other than a cautionary reminder regarding BBs initiation (BBs 'should usually be initiated in stable patients and used only with caution in recently decompensated patients'). Yet, even in the absence of evidence from randomized trials, clinical practice shifted to an introduction or up-titration of ACE-I/ARBs and BBs during hospital stay for a cardiovascular reason or soon after discharge. 17, 18 This concept was strongly supported by Fonarow 17, 19 and is now a key feature of the American Heart Association's Get with the Guidelines program. 20 However, evidence-based therapies of chronic HF are not systematically initiated or up-titrated during in-patient treatment. 21 Patients hospitalized for worsening HF are often discharged on the same pre-admission medications. 22, 23 The occurrence of worsening renal function caused by high-dose loop diuretics or renin -angiotensin system blockers may partly explain the lack of treatment intensification. In addition, during the weeks or months following discharge, little initiation or up-titration of HF treatments occurs.
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Figure 2 Survival curves for cardiovascular death or hospitalization for heart failure, hospitalization for heart failure, and all-cause mortality in patients in the eplerenone and placebo groups according to the timing since CVH.
Concerns about initiating MRAs shortly after admission or discharge for worsening HF appear to be even stronger than held for ACE-I/ARB and BBs, at least as judged by the even lower rate of prescription of MRAs. 8,21,25 -27 Most studies report MRA prescription in less than one-third of eligible patients, 8, 21, 25, 27 whereas prescription rates of ACE-I/ARBs and BBS are usually more than 70%. 21,25 -27 Changes in prescription pattern take time.
The EMPHASIS-HF trial 6 was published in 2011, i.e. much later than the trials focusing and ACE-I, ARBs, and BBs. However, despite the publication of RALES in severe systolic HF in 1999, and the publication of the EPHESUS trial in 2003, low prescription rates of MRAs persisted in eligible patients in reports based on data acquired at the end of the 2000s. 27, 28 One of the main explanations for the disconnection between guideline recommendations and clinical implementation is likely to be safety concerns regarding renal function and hyperkalaemia. A higher incidence of hospitalization for hyperkalaemia has been observed after the publication of the RALES trial. 29 In addition, patients at high risk of hyperkalaemia and/or worsening renal function are often thought to be under-represented in the MRA clinical trials.
6,7
However, we recently published a pre-specified subset analysis of EMPHASIS-HF, which showed that (i) a quarter of the patients randomized to eplerenone were older than 75 or had mild renal dysfunction and (ii) the benefit from eplerenone was significant in these patients at high risk for hyperkalaemia and/or worsening renal function. 30 Consequently, in patients with chronic HF with reduced LVEF and mild symptoms, meeting specific inclusion and exclusion criteria of EMPHASIS-HF, eplerenone is both efficacious and safe when carefully monitored. In addition, in this study, we further demonstrated that the adverse event rate was unaffected by the timing of initiation of eplerenone. Specifically, the increase in the risk of hyperkalaemia with eplerenone was similar in the ,42 and 42+ days groups. As a result, our analysis provides strong evidence of safety of an early initiation of eplerenone after a CVH. These results, taken together with the significant benefit associated with eplerenone in patients at high risk for hyperkalaemia and/or worsening renal 
Clinical perspective
Patients with HF hospitalized for CV reasons continue to suffer from an exceedingly high rate of adverse outcomes. The effectiveness of the currently available disease-modifying HF drugs has not been tested in adequately powered trials during or early after a CVH. 31 MRAs have been hypothesized to be good candidates for the treatment of acute HF syndromes. 32, 33 However, MRAs continue to be prescribed infrequently in eligible patients, probably because of concerns regarding their safety in patients at high risk for hyperkalemia and/or worsening renal function. We provide evidence that eplerenone reduces the high post-discharge event rate after a CVH in patients with systolic HF. We also provide evidence of the safety of eplerenone initiated early after discharge. Our results support the wider use of eplerenone early after a CVH in patients with systolic HF and mild symptoms and no contraindication to an MRA and with careful monitoring as conducted in the EMPHASIS-HF trial. Furthermore, our results suggest that randomized studies investigating inhospital initiation and up-titration of MRAs are worth undertaking.
Limitations
This is a post hoc analysis of a clinical trial that was not powered to identify treatment effect modification according to the timing of treatment initiation. In addition, for power purposes, timing since prior hospitalization and randomization was dichotomized at its median. We did not find effect modification (i.e. interaction) in this analysis, but non-linear interaction modelling or large sample size might have resulted in different results. Given the clinical trial nature of this study, and the inherent differences between clinical trials and registries, different effect modifications might be observed in the setting of usual care.
Conclusion
Eplerenone is safe and improves survival and prevents re-admission when initiated soon after a CVH in patients with systolic HF and mild symptoms. Initiation of eplerenone early after discharge from a CVH, including discharge from a HF hospitalization, should be encouraged, in patients meeting the inclusion criteria of EMPHASIS-HF. Merck, Forest Laboratories, and Novartis; grant support from Forest Laboratories and Novartis; and stock options from Relypsa, BG Medicine, Nile Therapeutics, and Aurasenc.
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